New Research Reveals Antiviral Potential in Specific Garlic Varieties, Leading to Product Launch at Gilroy Garlic Festival

Nick Diamantopoulos, founder of SupaG Health Pty Ltd, will unveil new garlic products at the renowned Gilroy Garlic Festival this July, following the publication of peer-reviewed studies demonstrating that certain garlic varieties possess significant antiviral properties. The findings, published in scientific journals including the Journal of Functional Foods and JSFA Reports, showed that specific garlic cultivars exhibited strong activity in laboratory studies against respiratory viruses such as SARS-CoV-2 (COVID-19) and Influenza A.

The in vitro studies demonstrated that only a small subset of garlic, regardless of growing location, exhibited meaningful antiviral activity. Notably, the same cultivars showed activity across both COVID-19 and Influenza A studies, suggesting that the properties are linked to the variety itself rather than growing conditions. According to Diamantopoulos, these findings fundamentally change how garlic should be viewed. 'For generations, garlic has been viewed as a natural remedy, however our research indicates that not all garlic is equal for health benefits, just as not all garlic is equal for nutrition and flavor,' he said.

This research program draws on more than 30 years of collection, breeding, and analysis, involving over 300 garlic varieties sourced from around the world. Diamantopoulos believes the discoveries may represent one of the most historically significant scientific developments in the garlic industry. 'The future of garlic nutraceuticals will not be commodity-based. It will be health-specific. We are moving from generic garlic products towards identified cultivars with targeted functional properties, proprietary formulations, traceable genetics and evidence-based health positioning,' he stated.

At the Gilroy Garlic Festival, the company will present a premium garlic supplement with a proprietary ingredient focused on specific formulations supported by peer-reviewed research. SupaG Health is actively pursuing distribution partnerships, nutraceutical and pharmaceutical collaborations, retail expansion opportunities, and further product development based on its proprietary research. Diamantopoulos and the SupaGarlic team will be available throughout the festival to discuss the published research, commercial development plans, and opportunities for strategic partnerships.

According to the published research, biological activity likely depends on the underlying garlic cultivar, extraction methods, formulation techniques, and processing controls. This creates opportunities to develop intellectual property around identified cultivars and proprietary formulations for the nutraceutical, functional food, and pharma sectors. 'This research establishes a scientific foundation for a new premium category within the health industry. Gilroy is the ideal place to begin that conversation with the world,' Diamantopoulos added.

It is important to note that the scientific studies referenced were conducted in laboratory settings and do not constitute clinical evidence in humans. These statements have not been evaluated by the U.S. Food and Drug Administration. SupaG Health products are not intended to diagnose, treat, cure, or prevent any disease.